DGS-Praxisleitlinie

Cannabis in der Schmerztherapie

Literatur

1. Handbibliothek

1. Ablin JN, Buskila D (2010) Emerging therapies for fibromyaliga: an update. Expert Opin Emerg Drugs 15: 521-533
2. Abrahams DI, Hilton JF, Leiser RJ et al (2003). Shortterm effects of cannabinoids in patients with HIV-1 infection: a rondomized, placebo-controlled clinical trial. Ann Intern Med 139:258-266
3. Aggarwal SK, Carter GT, Sullivan MD et al (2009) Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. J Opioid Manag. 5:257-286
4. Arzneimittelkommission der deutschen Ärzteschaft, Fachausschuss der Bundesärztekammer, der Kassenärztlichen Bundesvereinigung und der Arzneimittelkommission der deutschen Ärzteschaft zu den Anträgen der Fraktion Bündnis 90/Die Grünen „Medizinische Verwendung von Cannabis erleichtern“ vom 27.11.2007 und der Fraktion. Die Linke „Cannabis zur medizinischen Behandlung freigeben“ vom 25.06.2008. vvv.adkae.de/Stellungnahmen/Weitere/2008
5. Asbridge M., Hayden JA, Cartwright JL (2012) Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 344:e536.
6. Basch E, Hesketh PJ, Kris MG et al (2011). Antiemetics: American society of clinical oncology clinical practice guideline update. J Oncol Pract 7:395-3978
7. Beal JE, Olson R, Laubenstein L et al (1995) Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10:89-97
8. Beal JE, Olson R, Lefkowitz L et al (1997) Longterm efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 14:7-14
9. Bedi G, Foltin RW, Gunderson EW et al (2010) Efficacy and tolerability of high –dose-dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. 212: 675-686
10. Brisbois TD, de Kock IH, Watanabe SM et al. (2011): Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 22, 2086-2093
11. Bundesministerium der Justiz und Verbraucherschutz. Gesetz über den Verkehr mit Betäubungsmitteln.http://www.gesetze-im-internet.de/btmg_1981/.
12. Cichewicz DA (2004) Synergistic interactions between cannabinoids and opioid analgetics, Life Sci 74: 1317-24
13. Craver C, Gayle J, Balu S et al (2011) Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States. J Med Econ 14:87-98
14. Davis MP (2008): Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investing Drugs 17:85-95
15. Deutscher Bundestag. Drucksache 18/4539. Angekündigte Erleichterungen bei der Behandlung mit Cannabis als Medizin http://dip21.bundestag.de/dip21/btd/18/045/1804539.
16. Fitzcharles MA, Ste-Marie PA, Ablin JN, Shir Y (2014) Comparison of Canadian and Israeli rheumatologists` understanding of cannabinoid use as a therapy for rheumatic diseases. Ann Rheum Dis 73(Suppl2):1177
17. Fitzcharles MA, Jamal S (2015) Expanding medical marijuana access in Canada: considerations for the rheumatologist. J Rheumatol 42:143-145
18. FletcherJ (2013) Marijuana is not a prescription medicine. CMAJ 185:369 (Editoral)
19. Freund TF, Katona I, Piomelli D (2003). Role of endogenous cannabinoids in synaptic signaling. Physio Rev 83:1017-1066
20. Gross H, Ebert MH, Faden VB et al (1983). A Double-blind trial of delta 9-tetrahydrocannobinol in primary anorexia nervosa. J. Clin Psychophamacol 3:165-171
21. Grotenhermen F, Müller-Vahl K (2012) The therapeutic potential of cannabis and cannabinoids. Dtsch. Ärzteblatt Int 109:495-501
22. Grotenhermen F, Häußermann K (2017) Cannabis Verordnungshilfe für Ärzte, Wissenschaftliche Verlagsgesellschaft Stuttgart , 1.Auflage
23. Haney M, Gunderson EW, Rabkin J et al (2007) Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J. Acquir Immune Defic Syndr 45: 545-554
24. Häuser W, Fitzcharles M-A, Radbruch L, Petzke F (2017) Cannabinoide in der Schmerz-und Palliativmedizin, Deutsches Ärzteblatt 114/38, S 627-633
25. Haney M, Rabkin J, Gunderson E, Foltin RW (2005). Dronabinol and marijuana in HIV (+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology (Berl) 181:170-178.
26. Hazekamp A, Grotenhermen F (2010) Review on clinical studies with cannabis and cannabinoids 2005 – 2009. Cannabinoids; 5 (special issue): 1-21
27. Health Canada (ed.) (2013) Information for health care professionals – cannabis and the cannabinoids. Health Canada, Controlled Substances and Tobacco Directorate, Ottawa
28. Health Canada. Marihuana for medical purposes – statistics. http://lois-lawsjustcegcca/eng/regulations/SOR-2001-227/FullTesthtml2010.
29. Hesketh PJ (2004). Understanding the pathobiology of chemotherapy-induced nausea and vomiting. Providing a basis for therapeutic progress. Oncology (Williston Park). 18:9-14
30. Higgins J, Green S (eds) (2011) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 The Cochrane Collaboration. London.
31. Hill KP (2015) Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA 313:2474-2483
32. Hoch E, Bonneton U. Thomasius R et al (2015) Risks associated with the non-medicinal use of cannabis. Dtsch. Ärtzebl. Int 112:271-278
33. Hocking CM, Kirchenadasse G (2014) Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer 22:1143-1151
34. Hoggart B,Ratcliffe S, Ehler E, et al (2015) A multicenter open-label, follow-on study to assess the long-term-maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain. J Neurol 262: 27-40
35. Jatoi A, Windschitl HE, Loprinzi CL et al (2002). Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20:567-573
36. Johnson JR, Burnell-Nugent M, Lossignol D et al (2010). Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39:167-179
37. Jordan K, Jahn F, Aapro M (2015) Recent developments in the preventions of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. An Oncol 26:1081-1090
38. Jordhoy MS, Kaasa S, Fayers P et al (1999). Challenges in palliative care research; recruitments, attrition and compliance: experience from a randomized controlled trial. Palliat. Med 13.299-310
39. Kaasa S, Hjermstad MJ, Lage JH (2006). Methodological and structural challenges in palliative care research: how have we fared in the last decades? Palliat Med 20:727-734
40. Kalant H (2001) Medicinal use of cannabis: history and current status. Pain Res Manag 6:80-91
41. Keeley PW (2009) Nausea and vomiting in people with cancer and other chronic diseases. BMJ Clin Evid 2009
42. Likar R, Pipam W, Köstenberger M, Neuwersch S (2017) Klinischer Einsatz von Cannabinoiden Z Palliativmed 18: 249-254
43. Liu J, Tan L, Zhang H et al (2015) QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist. Eur J Cancer Care (Engl) 24:436-443
44. Lutge EE, Gray A, Siegfried N (2013). The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database Syst. Rev 4:CD005Cochrane Database Syst. Rev 4:CD005175
45. Lynch ME, Campbell F (2011) Cannabinoids for treatment of chronic non-cancer pain: a systematic review of randomized trials. Br J Clin Pharmacol. 72: 735-744
46. Machado Rocha FC, Stefano SC, De Cassia Haiek R et al (2008). Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Eng) 17:431-443
47. Mann RE, Stoduto G, Lalomitenu A, Asbridge M, Smart RG, Wickens CM (2010), Self-reported collision risk associated with cannabis use and driving after cannabis use among Ontario adults. Traffic Inj Pre 11:115-122
48. Martin-Sanchez E, Furukawa TA, Taylor J et al (2009) Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med 10: 1353-1368
49. Mechoulam R, Gaoni Y (1965) A total synthesis of DL-delta-1-tetrahydrocannabinaol, the active constituent of hashish. J Am Chem Soc 20 (87):3273-3275
50. Mechoulam R (2014) Looking ahead after 50 years of research on cannabinoids. Cannabinoids 5:1-15
51. Medical marijuana: guidance for Canadian Doctors. https://www.cmpa-acpm.ca/home.
52. Moulin, DE, Boulanger, A.Clarke AJ. et al. (2014) Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society, Pain Res Manag 19: 328-335

53. Narang S et al (2008) Efficacy of Dronabinol as an Adjuvant Treatment for Chronic Pain Patients on Opioid Therapy. J Pain 9(3): 254-64
54. Noyes R, Brunk SF, Avery DA, Canter AC (1975). The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 18:84-89
55. Paglia-Boak A, Adlaf EM, Mann RE, Rehm J. Drug use among Ontario students: 1977 to 2009 OS-DUHS Highlights Toronto, ON, Canada: Centre for Addiction and Mental Health; 2011
56. Palli SR, Grabner M, Quimbo RA et al (2015). The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting. Cancer Manag Res: 175-188
57. Pertwee RG (2012) Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibillities. Philos Trans R Soc Land B Biol Sci 367:3353-3363
58. Phillips RS, Gopaul S, Gibson F et al (2010). Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database Syst Rev (9): CD007786
59. Portenoy RK, Ganae-Motan ED, Allende S et al (2012). Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 13:438-449
60. Regelson W, Butler JR, Schulz J (1976). Delta-9-THC as an effective antidepressant and appetitestimulating agent in advanced cancer patients. In: Braude MC, Szara S (Hrsg.) Pharmacology of Marihuana. Raven Press, New York. S 763-775
61. Rog DJ, Nurmikko TJ, Young CA (2007) Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 29: 2068-2079
62. Roila F, Herrstedt J, Aapra M et al (2010) Guidelinde update for MASCC and ESMA in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21 (Suppl 5): v232-243
63. Santana TA, Trufelli DC, Matos LL et al (2015). Meta-analysis of adjunctive non-NK1 receptor antagonist medications for the control of acute and delayed chemotherapy-induced nausea and vomiting. Support Care Cancer 23:213-222
64. Sigurdardottir KR, Haugen DF, van der Rijt CCD et al (2010) Clinical priorities, barriers and solutions in end-of-life cancer care research across Europe. Report from a workshop. Eur J Cancer 46:1815-1822
65. Smith LA, Azariah F, Lavender VT et al (2015). Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database SystRev 11:CD009464
66. Smith PA et al. Low dose combination of morphine and delta9-tetra- hydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur J Pharmacol 2007;571(2-3):129–37 


67. Staquet M, Gantt C, Machin D (1978). Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther 23:397-401
68. Strasser F (2006). Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group.J Clin Oncol 24:3394-3400
69. Struwe M, Kaempfer SH, Geiger CJ et al (1991). Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 27:827-831
70. Tafelski S, Häuser W, Schäfer M (2016) Efficacy, tolerability and safety of cannabinoids for chemotherapy-induced nausea and vomiting-a systematic review of systematic reviews. Schmerz doi:10.1007/s00482-015-0092-3
71. Tait RJ, Caldicott D, Mountain D et al (2015). A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila) 54:1-13
72. The College of Family Physicians Canada: medical marijuana position statement. http://www.cfpc.ca/Home/.
73. Timpone JG, Wright DJ, Li N et al (1997): The safety and pharmacokinetics of single-agent and combination therapy with megestol acetate and dronabinol for the treatmend of HIV wasting syndrome. AIDS res Hum Retroviruses 13:305-313
74. Todaro B (2012). Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw 10:487-492
75. Tramer MR, Carroll D, Campbell FA et al (2001). Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323:16-21
76. Van Den Elsen GA, Ahmed AL, Lammers M et al (2014). Efficacy and safety of medical cannabinoids in older subjects: a systematic review. Ageing Res. Rev. 14:56-64
77. Van Sickle MD, Duncan M, Kingsley PJ et al (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310: 329-332
78. Verwaltungsgericht Köln. Eigenanbau von Cannabis zu therapeutischen Zwecken kann in Einzelfällen genehmigt werden. Vvv.vg-koeln.nrw.de/behoerde/presse/Pressemitteilung/Archiv/2014/14_140722/index.php.
79. Volicer L, Stelly M, Morris J et al (1997). Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer´s disease. Int J Geriatr Psychiatry 12:913-919
80. Wang XF, Feng Y, Chen Y et al (2014). A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Scientific reports 4:4813
81. Ware MA. et al, 2005 The medical use of cannabis in the UK: results of a nation wide survey). Int. J. Clin Pract 3: 291-295,
82. Zadikoff C. Wadia PM, Miyasaki J et al (2011). Cannabinoid, CB1 agonists in cervical dystonia: failure in a phase lla randomized controlled trial. Basal Ganglia 1:91-95. Doi 10.1016/j.baga.2011.04.002
83. Zajicek JP, Sanders HP, Wright DE et al (2005) Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 76: 1664-1669
84. Zhang MW, Ho RCM (2015) The cannabis dilemma: a review of its associated risks and clinical efficacy. J Addict 2015:707596.
85. Zutt M, Hänßle H, Emmert S et al (2006). Dronabinol zur supportiven Therapie metastasierter maligner Melanome mit Lebermetastasen. Hautarzt 57:423-427

2. Datenbankrecherche



lfd. Nr.


Autor

XIII-2:Datenbankrecherche


Titel

12/2017


Quelle


Evi-
denz
grad


1


- -


MEDICAL CANNABIS


Harefuah. 2016 Feb;155(2):79-82, 133


- -

2

- -

Pain Relief Now!

Consum Rep. 2016 Jun;81(6):28-39.

- -

3

- -

Does Cannabis have a role in the tehrapy of rehumatic conditions?

Harefuah. 2016 Feb;155(2):83-4.

III

4

- -

MEDICAL CANNABIS - A SOURCE FOR A NEW TREATMENT FOR AUTOIMMUNE DISEASE?

Harefuah. 2016 Feb;155(2):74-8, 133

III

5

Aamir T1

New Zealand doctors should be allowed to prescribe cannabis for pain: No

J Prim Health Care. 2015 Jun 1;7(2):160-1.

IV

6

Ablin J1, Ste-Marie PA2,3, Schäfer M4, Häuser W5,6, Fitzcharles MA2,3.

Medical use of cannabis products: Lessons to be learned from Israel and Canada

Schmerz. 2016 Feb;30(1):3-13. doi: 10.1007/s00482-015-0083-4

III

7

Abrams DI1, Guzman M2.

Cannabis in cancer care

Clin Pharmacol Ther. 2015 Jun;97(6):575-86. doi: 10.1002/cpt.108. Epub 2015 Apr 17.

IV

8

Aggarwal SK1.

Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results

Clin J Pain. 2013 Feb;29(2):162-71. doi: 10.1097/AJP.0b013e31824c5e4c.

Ia

9

Alaniz VI1, Liss J, Metz TD, Stickrath E

Cannabinoid hyperemesis syndrome: a cause of refractory nausea and vomiting in pregnancy

Obstet Gynecol. 2015 Jun;125(6):1484-6. doi: 10.1097/AOG.0000000000000595.

III

10

Albertson TE1, Chenoweth JA1, Colby DK1, Sutter ME1.

The Changing Drug Culture: Medical and Recreational Marijuana.

III

11

Alexander SP1.

Therapeutic potential of cannabis-related drugs.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:157-66. doi:10.1016/j.pnpbp.2015.07.001. Epub 2015 Jul 26.

IV

12

Andrade C1.

Cannabis and neuropsychiatry, 1: benefits and risks.

J Clin Psychiatry. 2016 May;77(5):e551-4. doi: 10.4088/JCP.16f10841

III

13

Andreae MH1, Carter GM2, Shaparin N3, Suslov K4, Ellis RJ5, Ware MA6, Abrams DI7, Prasad H8, Wilsey B8, Indyk D4, Johnson M9, Sacks HS4.

Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data

Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data

Ia

14

Andresen SR1, Biering-Sørensen F, Hagen EM, Nielsen JF, Bach FW, Finnerup NB

Cannabis use in persons with traumatic spinal cord injury in Denmark

J Rehabil Med. 2017 Jan 31;49(2):152-160. doi: 10.2340/16501977-2105

III

15

Ashrafioun L1, Bohnert KM2, Jannausch M2, Ilgen MA2

Characteristics of substance use disorder treatment patients using medical cannabis for pain.

Addict Behav. 2015 Mar;42:185-8. doi: 10.1016/j.addbeh.2014.11.024. Epub 2014 Nov 26.

IIa

16

Avello L M1, Pastene N E1, Fernández R P1, Córdova M P1

Therapeutic potential of Cannabis sativa

Rev Med Chil. 2017 Mar;145(3):360-367. doi: 10.4067/S0034-98872017000300010

IV

17

Babson KA1, Sottile J2, Morabito D3

Cannabis, Cannabinoids, and Sleep: a Review of the Literature

Curr Psychiatry Rep. 2017 Apr;19(4):23. doi: 10.1007/s11920-017-0775-9

III

18

Bachhuber MA1, Saloner B2, Cunningham CO3, Barry CL4

Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010.

JAMA Intern Med. 2014 Oct;174(10):1668-73. doi: 10.1001/jamainternmed.2014.4005.

III

19

Baggio S, Studer J, Mohler-Kuo M, Daeppen JB, Gmel G.

Non-medical prescription drug and illicit street drug use among young Swiss men and associated mental health issues.

Int J Adolesc Med Health. 2014;26(4):525-30. doi: 10.1515/ijamh-2013-0330.

III

20

Banwell E1, Pavisian B2, Lee L3, Feinstein A4

Attitudes to cannabis and patterns of use among Canadians with multiple sclerosis.

Mult Scler Relat Disord. 2016 Nov;10:123-126. doi: 10.1016/j.msard.2016.09.008. Epub 2016 Sep 28.

III

21

Bar-Sela G, Avisar A, Batash R, Schaffer M

Is the clinical use of cannabis by oncology patients advisable?

Curr Med Chem. 2014 Jun;21(17):1923-30.

IV

22

Baron EP1.

Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….

Headache. 2015 Jun;55(6):885-916. doi: 10.1111/head.12570. Epub 2015 May 25.

IV

23

Beaulieu P1,2, Boulanger A3,4, Desroches J5, Clark AJ6.

Medical cannabis: considerations for the anesthesiologist and pain physician

Can J Anaesth. 2016 May;63(5):608-24. doi: 10.1007/s12630-016-0598-x. Epub 2016 Feb 5.

III

24

Beech RA1, Sterrett DR2, Babiuk J3, Fung H4

Cannabinoid Hyperemesis Syndrome: A Case Report and Literature Review.

J Oral Maxillofac Surg. 2015 Oct;73(10):1907-10. doi: 10.1016/j.joms.2015.03.059. Epub 2015 Apr 10.

III

25

Belendiuk KA1, Baldini LL2, Bonn-Miller MO3,4,5.

Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders.

Addict Sci Clin Pract. 2015 Apr 21;10:10. doi: 10.1186/s13722-015-0032-7.

III

26

Benbadis SR1, Sanchez-Ramos J, Bozorg A, Giarratano M, Kalidas K, Katzin L, Robertson D, Vu T, Smith A, Zesiewicz T

Medical marijuana in neurology

Expert Rev Neurother. 2014 Dec;14(12):1453-65. doi: 10.1586/14737175.2014.985209

IV

27

Bennett M1, Paice JA1, Wallace M1

Pain and Opioids in Cancer Care: Benefits, Risks, and Alternatives

Am Soc Clin Oncol Educ Book. 2017;37:705-713. doi: 10.14694/EDBK_180469

IV

28

Benyamina A, Reynaud M.

Therapeutic use of cannabis derivatives

Rev Prat. 2014 Feb;64(2):165-8.

IV

29

Bertolino J1, Abdo L2, Khau D3, Meckenstock R3, Sautereau N1, Jean E1, Greder-Belan A3, Frances Y1, Cabane J2, Granel B

Cannabinoid hyperemesis syndrome: about 6 cases

Rev Med Interne. 2015 Oct;36(10):694-7. doi: 10.1016/j.revmed.2014.11.012. Epub 2014 Dec 26.

III

30

Bertrand A1, Boyle H2, Moreaux J2, Guillot L3, Chvetzoff G2, Charbonnel JF3, Marec-Berard P2.

Does consumption of tobacco, alcohol, and cannabis in adolescents and young adults with cancer affect the use of analgesics during hospitalizations?

Arch Pediatr. 2016 Apr;23(4):353-9. doi: 10.1016/j.arcped.2015.12.022. Epub 2016 Mar 8

III

31

Bierut T1, Krauss MJ2, Sowles SJ2, Cavazos-Rehg PA3

Exploring Marijuana Advertising on Weedmaps, a Popular Online Directory.

III

32

Birdsall SM1, Birdsall TC2, Tims LA2

The Use of Medical Marijuana in Cancer.

Curr Oncol Rep. 2016 Jul;18(7):40. doi: 10.1007/s11912-016-0530-0

III

33

Bjurström J1, Friis S2.

Cykliska kräkningar och buksmärta av långvarig cannabisanvändning - Cannabisrelaterat hyperemesissyndrom »ny« diagnos som lindras av varma duschar och bad

Lakartidningen. 2016 May 19;113. pii: DXUM

III

34

Bodmer M, Enzler F, Liakoni E, Bruggisser M, Liechti ME

Acute cocaine-related health problems in patients presenting to an urban emergency department in Switzerland: a case series.

BMC Res Notes. 2014 Mar 25;7:173. doi: 10.1186/1756-0500-7-173.

III

35

Boehnke KF1, Litinas E2, Clauw DJ3.

Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain.

J Pain. 2016 Jun;17(6):739-44. doi: 10.1016/j.jpain.2016.03.002. Epub 2016 Mar 19.

III

36

Bohnert KM1, Perron BE2, Ashrafioun L3, Kleinberg F4, Jannausch M4, Ilgen MA4.

Positive posttraumatic stress disorder screens among first-time medical cannabis patients: prevalence and association with other substance use

Addict Behav. 2014 Oct;39(10):1414-7. doi: 10.1016/j.addbeh.2014.05.022. Epub 2014 Jun 2

III

37

Bonn-Miller MO, Boden MT, Bucossi MM, Babson KA.

Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users.

Am J Drug Alcohol Abuse. 2014 Jan;40(1):23-30. doi: 10.3109/00952990.2013.821477. Epub 2013 Nov 8.

III

38

Bonnet U1.

An Overlooked Victim of Cannabis: Losing Several Years of Well-being and Inches of Jejunum on the Way to Unravel Her Hyperemesis Enigma.

Clin Neuropharmacol. 2016 Jan-Feb;39(1):53-4. doi: 10.1097/WNF.0000000000000118

III

39

Borgelt LM1, Franson KL, Nussbaum AM, Wang GS

The pharmacologic and clinical effects of medical cannabis

Pharmacotherapy. 2013 Feb;33(2):195-209. doi: 10.1002/phar.1187.

IV

40

Bostwick JM

The use of cannabis for management of chronic pain

Gen Hosp Psychiatry. 2014 Jan-Feb;36(1):2-3. doi: 10.1016/j.genhosppsych.2013.08.004. Epub 2013 Oct 1.

IV

41

Bostwick JM1, Reisfield GM, DuPont RL

Clinical decisions. Medicinal use of marijuana

N Engl J Med. 2013 Feb 28;368(9):866-8. doi: 10.1056/NEJMclde1300970. Epub 2013 Feb 20.

IV

42

Boychuk DG, Goddard G, Mauro G, Orellana MF

The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review.

J Oral Facial Pain Headache. 2015 Winter;29(1):7-14. doi: 10.11607/ofph.1274.

Ia

43

Brewerton TD1, Anderson O2.

Cannabinoid hyperemesis syndrome masquerading as an eating disorder.

Int J Eat Disord. 2016 Aug;49(8):826-9. doi: 10.1002/eat.22515. Epub 2016 Feb 4.

III

44

Brucki SM1, Frota NA1, Schestatsky P1, Souza AH1, Carvalho VN1, Manreza ML1, Mendes MF1, Comini-Frota E1, Vasconcelos C1, Tumas V1, Ferraz HB1, Barbosa E1, Jurno ME1.

Cannabinoids in neurology--Brazilian Academy of Neurology

Arq Neuropsiquiatr. 2015 Apr;73(4):371-4. doi: 10.1590/0004-282X20150041. Epub 2015 Apr 1.

IV

45

Brunt TM1, van Genugten M, Höner-Snoeken K, van de Velde MJ, Niesink RJ.

Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis

J Clin Psychopharmacol. 2014 Jun;34(3):344-9. doi: 10.1097/JCP.0000000000000129.

III

46

Burger BM1, Chavis PS, Purvin V.

A weed by any other name.

Surv Ophthalmol. 2013 Mar-Apr;58(2):176-83. doi: 10.1016/j.survophthal.2012.02.005. Epub 2012 Jul 20.

III

47

Burgos García A1, Froilán Torres C1, Tavecchia M1

Endoscopic removal of a hashish packet

Rev Esp Enferm Dig. 2017 Mar;109(3):235. doi: 10.17235/reed.2017.4504/2016

III

48

Cairns EA1, Kelly MEM2.

Why support a separate medical access framework for cannabis?

IV

49

Cameron C1, Watson D, Robinson J

Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation

J Clin Psychopharmacol. 2014 Oct;34(5):559-64. doi: 10.1097/JCP.0000000000000180.

III

50

Canazza I1, Ossato A1, Trapella C2, Fantinati A2, De Luca MA3, Margiani G3, Vincenzi F4, Rimondo C5, Di Rosa F6, Gregori A6, Varani K4, Borea PA4, Serpelloni G7, Marti M8,9.

Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on "tetrad", sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies.

Psychopharmacology (Berl). 2016 Oct;233(21-22):3685-3709. Epub 2016 Aug 15.

IIa

51

Carlini BH1, Garrett SB1, Carter GT2.

Medicinal Cannabis: A Survey Among Health Care Providers in Washington State

Am J Hosp Palliat Care. 2017 Feb;34(1):85-91. doi: 10.1177/1049909115604669. Epub 2016 Jul 11.

III

52

Carter GT1, Javaher SP, Nguyen MH, Garret S, Carlini BH

Re-branding cannabis: the next generation of chronic pain medicine?

Pain Manag. 2015;5(1):13-21. doi: 10.2217/pmt.14.49.

IV

53

Cary RM1, Bragg C1, Mukherjee J2.

Pleuritic chest pain and fluid levels on imaging in a heavy cannabis smoker

BMJ Case Rep. 2015 Feb 3;2015. pii: bcr2014208064. doi: 10.1136/bcr-2014-208064.

III

54

Castaneto MS1, Gorelick DA2, Desrosiers NA1, Hartman RL1, Pirard S3, Huestis MA4.

Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications

Drug Alcohol Depend. 2014 Nov 1;144:12-41. doi: 10.1016/j.drugalcdep.2014.08.005. Epub 2014 Aug 18.

IV

55

Choo EK1, Feldstein Ewing SW2, Lovejoy TI3

Opioids Out, Cannabis In: Negotiating the Unknowns in Patient Care for Chronic Pain

JAMA. 2016 Nov 1;316(17):1763-1764. doi: 10.1001/jama.2016.13677

III

56

Clark JM1, Cao Y2, Krause JS3.

Risk of Pain Medication Misuse After Spinal Cord Injury: The Role of Substance Use, Personality, and Depression

J Pain. 2017 Feb;18(2):166-177. doi: 10.1016/j.jpain.2016.10.011. Epub 2016 Nov 9.

III

57

Cohen NL1, Heinz AJ1,2, Ilgen M3,4, Bonn-Miller MO1,2,5,6

Pain, Cannabis Species, and Cannabis Use Disorders

Stud Alcohol Drugs. 2016 May;77(3):515-20

III

58

Cooper ZD1, Haney M2.

Sex-dependent effects of cannabis-induced analgesia

Drug Alcohol Depend. 2016 Oct 1;167:112-20. doi: 10.1016/j.drugalcdep.2016.08.001. Epub 2016 Aug 5.

IIa

59

Crowley D1, Collins C1, Delargy I1, Laird E2, Van Hout MC3,4.

Irish general practitioner attitudes toward decriminalisation and medical use of cannabis: results from a national survey.

Harm Reduct J. 2017 Jan 13;14(1):4. doi: 10.1186/s12954-016-0129-7

III

60

Cullen T.

Q & A with grower Tim Cullen [interview by Mary Winter].

State Legis. 2015 Mar;41(3):25.

IV

61

Davis MP1

Cannabinoids for Symptom Management and Cancer Therapy: The Evidence

Natl Compr Canc Netw. 2016 Jul;14(7):915-22

III

62

de Tommaso M1, Kunz M2, Valeriani M3

Therapeutic approach to pain in neurodegenerative diseases: current evidence and perspectives.

Expert Rev Neurother. 2017 Feb;17(2):143-153. doi: 10.1080/14737175.2016.1210512. Epub 2016 Jul 26.

III

63

de Vries M1, van Rijckevorsel DC, Wilder-Smith OH, van Goor H.

Dronabinol and chronic pain: importance of mechanistic considerations.

Expert Opin Pharmacother. 2014 Aug;15(11):1525-34. doi: 10.1517/14656566.2014.918102. Epub 2014 May 12.

Ia

64

Degenhardt L1, Lintzeris N2, Campbell G3, Bruno R4, Cohen M5, Farrell M3, Hall WD6.

Experience of adjunctive cannabis use for chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study.

Drug Alcohol Depend. 2015 Feb 1;147:144-50. doi: 10.1016/j.drugalcdep.2014.11.031. Epub 2014 Dec 10.

III

65

Deiana S1.

Medical use of cannabis. Cannabidiol: a new light for schizophrenia?

Drug Test Anal. 2013 Jan;5(1):46-51. doi: 10.1002/dta.1425. Epub 2012 Oct 25.

IV

66

Deshpande A, Mailis-Gagnon A, Zoheiry N, Lakha SF.

Efficacy and adverse effects of medical marijuana for chronic noncancer pain: Systematic review of randomized controlled trials.

Can Fam Physician. 2015 Aug;61(8):e372-81.

Ia

67

Desjardins N1, Jamoulle O1, Taddeo D1, Stheneur C2

Cannabinoid Hyperemesis Syndrome in a 17-Year-Old Adolescent

J Adolesc Health. 2015 Nov;57(5):565-7. doi: 10.1016/j.jadohealth.2015.07.019. Epub 2015 Sep 12.

III

68

Desjardins N1, Stheneur C2

Cannabinoid hyperemesis syndrome: A review of the literature

Arch Pediatr. 2016 Jun;23(6):619-23. doi: 10.1016/j.arcped.2016.01.016. Epub 2016 Apr 12.

III

69

Dezieck L1, Hafez Z2, Conicella A1, Blohm E1, O'Connor MJ3, Schwarz ES2, Mullins ME2

Resolution of cannabis hyperemesis syndrome with topical capsaicin in the emergency department: a case series

Clin Toxicol (Phila). 2017 Sep;55(8):908-913. doi: 10.1080/15563650.2017.1324166. Epub 2017 May 11

III

70

Ebert T, Zolotov Y, Eliav S, Ginzburg O, Shapira I, Magnezi R

Assessment of Israeli Physicians' Knowledge, Experience and Attitudes towards Medical Cannabis: A Pilot Study.

Isr Med Assoc J. 2015 Jul;17(7):437-41.

III

71

Eiden C, Ripault MP, Larrey D, Faillie JL, Pinzani V, Pageaux GP, Peyrière H.

Acute hepatitis and renal failure related to intranasal buprenorphine misuse: case report and analysis of cases reported to the French network for drug monitoring.

Ann Pharmacother. 2013 Dec;47(12):1721-6. doi: 10.1177/1060028013507429. Epub 2013 Oct 15.

III

72

Eisenberg E, Ogintz M, Almog S.

The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study

J Pain Palliat Care Pharmacother. 2014 Sep;28(3):216-25. doi: 10.3109/15360288.2014.941130. Epub 2014 Aug 13.

IIa

73

Eisenstein M.

Medical marijuana: Showdown at the cannabis corral

Nature. 2015 Sep 24;525(7570):S15-7. doi: 10.1038/525S15a.

IV

74

Elliott DA1, Nabavizadeh N2, Romer JL2, Chen Y3, Holland JM2.

Medical marijuana use in head and neck squamous cell carcinoma patients treated with radiotherapy.

Support Care Cancer. 2016 Aug;24(8):3517-24. doi: 10.1007/s00520-016-3180-8. Epub 2016 Mar 23.

III

75

Erbe B

Cannabis - medicinal use

Dtsch Med Wochenschr. 2014 Jan;139(3):74-5.

IV

76

Erickson B, Kiser K.

Cannabis and chronic pain.

Minn Med. 2016 Jan-Feb;99(1):8-9.

III

77

Fatma H1, Mouna B, Leila M, Radhouane D, Taoufik N.

Cannabis: a rare cause of acute pancreatitis

Clin Res Hepatol Gastroenterol. 2013 Feb;37(1):e24-5. doi: 10.1016/j.clinre.2012.05.004. Epub 2012 Jun 29

III

78

Feinstein A1, Banwell E2, Pavisian B2.

What to make of cannabis and cognition in MS: In search of clarity amidst the haze.

IV

79

Fernández-Villa T1, Alguacil Ojeda J, Almaraz Gómez A, Cancela Carral JM, Delgado-Rodríguez M, García-Martín M, Jiménez-Mejías E, Llorca J, Molina AJ, Ortíz Moncada R, Valero-Juan LF, Martín V.

Problematic Internet Use in University Students: associated factors and differences of gender.

Adicciones. 2015 Dec 15;27(4):265-75.

III

80

Fijał K1, Filip M.

Clinical/Therapeutic Approaches for Cannabinoid Ligands in Central and Peripheral Nervous System Diseases: Mini Review.

Clin Neuropharmacol. 2016 Mar-Apr;39(2):94-101. doi: 10.1097/WNF.0000000000000132.

III

81

Finn K1.

Sequelae of Cannabis as Medicine.

Pain Med. 2015 Jul;16(7):1447-9. doi: 10.1111/pme.12736. Epub 2015 Jun 24.

IV

82

Fitzcharles MA1, Ste-Marie PA, Clauw DJ, Jamal S, Karsh J, LeClercq S, McDougall JJ, Shir Y, Shojania K, Walsh Z

Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaints

BMC Musculoskelet Disord. 2014 Jul 30;15:258. doi: 10.1186/1471-2474-15-258.

III

83

Fitzcharles MA1, Ste-Marie PA1, Häuser W2, Clauw DJ3, Jamal S4, Karsh J5, Landry T6, Leclercq S7, Mcdougall JJ8, Shir Y1, Shojania K9, Walsh Z4.

Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials.

Arthritis Care Res (Hoboken). 2016 May;68(5):681-8. doi: 10.1002/acr.22727

Ia

84

Fitzcharles MA1,2, Baerwald C3, Ablin J4, Häuser W5,6.

Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials.

Schmerz. 2016 Feb;30(1):47-61. doi: 10.1007/s00482-015-0084-3.

Ia

85

Fitzcharles MA1,2,3, Häuser W4,5.

Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases

Curr Rheumatol Rep. 2016 Dec;18(12):76. doi: 10.1007/s11926-016-0625-5

III

86

Fitzpatrick JK1, Downer EJ2

Toll-like receptor signalling as a cannabinoid target in Multiple Sclerosis.

Neuropharmacology. 2017 Feb;113(Pt B):618-626. doi: 10.1016/j.neuropharm.2016.04.009. Epub 2016 Apr 11.

III

87

Fong C1, Matusow H, Cleland CM, Rosenblum A

Characteristics of Non-Opioid Substance Misusers Among Patients Enrolling in Opioid Treatment Programs: A Latent Class Analysis.

J Addict Dis. 2015;34(2-3):141-50. doi: 10.1080/10550887.2015.1059226.

III

88

Frisch S

Medical cannabis: US researchers battle for access to the plant.

BMJ. 2014 Nov 21;349:g6997. doi: 10.1136/bmj.g6997.

IV

89

Gabbai AA1, Castelo A, Oliveira AS.

HIV peripheral neuropathy

Handb Clin Neurol. 2013;115:515-29. doi: 10.1016/B978-0-444-52902-2.00029-

IV

90

Gazdek D.

Marijuana for medical purposes--public health perspective

Lijec Vjesn. 2014 Jul-Aug;136(7-8):192-9.

IV

91

Gentile G1, Frauger E2, Giocanti A3, Pauly V3, Orleans V3, Amaslidou D2, Thirion X3, Micallef J2; Réseau national des centres d’addictovigilance

Characteristics of subjects under opiate maintenance treatment in primary care using the OPEMA data 2013

Therapie. 2016 Jun;71(3):307-13. doi: 10.1016/j.therap.2016.02.001. Epub 2016 Feb 5.

III

92

Geresu B1.

Khat (Catha edulis F.) and cannabinoids: Parallel and contrasting behavioral effects in preclinical and clinical studies.

Pharmacol Biochem Behav. 2015 Nov;138:164-73. doi: 10.1016/j.pbb.2015.09.019.

IV

93

Goldenberg M1, Reid MW1, IsHak WW2, Danovitch I1.

The impact of cannabis and cannabinoids for medical conditions on health-related quality of life: A systematic review and meta-analysis.

Drug Alcohol Depend. 2017 May 1;174:80-90. doi: 10.1016/j.drugalcdep.2016.12.030. Epub 2017 Mar 1.

Ia

94

Goyal H1, Singla U, Gupta U, May E.

Role of cannabis in digestive disorders

Eur J Gastroenterol Hepatol. 2017 Feb;29(2):135-143. doi: 10.1097/MEG.0000000000000779

III

95

Graham J1, Barberio M2, Wang GS3

Capsaicin Cream for Treatment of Cannabinoid Hyperemesis Syndrome in Adolescents: A Case Series

Pediatrics. 2017 Dec;140(6). pii: e20163795. doi: 10.1542/peds.2016-3795. Epub 2017 Nov 9.

III

96

Grant I1.

Medical Use of Cannabinoids.

JAMA. 2015 Oct 27;314(16):1750-1. doi: 10.1001/jama.2015.11429.

- -

97

Grant I1.

Medicinal cannabis and painful sensory neuropathy.

Virtual Mentor. 2013 May 1;15(5):466-9. doi: 10.1001/virtualmentor.2013.15.5.oped1-1305.

IV

98

Grosshans M, Lemenager T, Vollmert C, Kaemmerer N, Schreiner R, Mutschler J, Wagner X, Kiefer F, Hermann D.

Pregabalin abuse among opiate addicted patients.

Eur J Clin Pharmacol. 2013 Dec;69(12):2021-5. doi: 10.1007/s00228-013-1578-5. Epub 2013 Aug 30.

III

99

Hagmann SG.

Scientific data are lacking

Dtsch Arztebl Int. 2013 Mar;110(10):174. doi: 10.3238/arztebl.2013.0174a. Epub 2013 Mar 8.

IV

100

Hantson P1, Di Fazio V, Del Mar Ramirez Fernandez M, Samyn N, Duprez T, van Pesch V

Susac-like syndrome in a chronic cocaine abuser: could levamisole play a role?

J Med Toxicol. 2015 Mar;11(1):124-8. doi: 10.1007/s13181-014-0422-3.

III

101

Hardy PA1.

New Zealand doctors should be allowed to prescribe cannabis for pain: Yes.

J Prim Health Care. 2015 Jun 1;7(2):158-9.

IV

102

Haroutounian S1, Ratz Y, Ginosar Y, Furmanov K, Saifi F, Meidan R, Davidson E.

The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain: A Prospective Open-label Study.

Clin J Pain. 2016 Dec;32(12):1036-1043.

IIa

103

Harrison AM1, Heritier F2, Childs BG3, Bostwick JM4, Dziadzko MA5.

Systematic Review of the Use of Phytochemicals for Management of Pain in Cancer Therapy.

Biomed Res Int. 2015;2015:506327. doi: 10.1155/2015/506327. Epub 2015 Oct 20.

III

104

Hasenoehrl C1, Storr M2,3, Schicho R1

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):329-337. doi: 10.1080/17474124.2017.1292851. Epub 2017 Feb 16

III

105

Hazekamp A1, Heerdink ER.

The prevalence and incidence of medicinal cannabis on prescription in The Netherlands

Eur J Clin Pharmacol. 2013 Aug;69(8):1575-80. doi: 10.1007/s00228-013-1503-y. Epub 2013 Apr 16.

III

106

Hefner K, Sofuoglu M, Rosenheck R

Concomitant cannabis abuse/dependence in patients treated with opioids for non-cancer pain.

Am J Addict. 2015 Sep;24(6):538-45. doi: 10.1111/ajad.12260. Epub 2015 Aug 5.

IV

107

Hermanns-Clausen M1, Kneisel S, Szabo B, Auwärter VPacher P1.

Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings.

Addiction. 2013 Mar;108(3):534-44. doi: 10.1111/j.1360-0443.2012.04078.x. Epub 2012 Nov 1.

III

108

Herrmann ES1, Weerts EM2, Vandrey R1.

Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users.

Exp Clin Psychopharmacol. 2015 Dec;23(6):415-21. doi: 10.1037/pha0000053. Epub 2015 Oct 12.

III

109

Hickey JL1, Witsil JC, Mycyk MB.

Haloperidol for treatment of cannabinoid hyperemesis syndrome

Am J Emerg Med. 2013 Jun;31(6):1003.e5-6. doi: 10.1016/j.ajem.2013.02.021. Epub 2013 Apr 10

III

110

Hua T1, Vemuri K2, Pu M3, Qu L1, Han GW4, Wu Y5, Zhao S5, Shui W5, Li S5, Korde A2, Laprairie RB6, Stahl EL6, Ho JH6, Zvonok N2, Zhou H2, Kufareva I7, Wu B8, Zhao Q8, Hanson MA9, Bohn LM10, Makriyannis A11, Stevens RC12, Liu ZJ13.

Crystal Structure of the Human Cannabinoid Receptor CB1

Cell. 2016 Oct 20;167(3):750-762.e14. doi: 10.1016/j.cell.2016.10.004

III

111

Huang WJ1, Chen WW1, Zhang X1

Endocannabinoid system: Role in depression, reward and pain control (Review).

Mol Med Rep. 2016 Oct;14(4):2899-903. doi: 10.3892/mmr.2016.5585. Epub 2016 Aug 1.

III

112

Ijaz F1, Iqbal Z2, Rahman IU3, Alam J4, Khan SM5, Shah GM6, Khan K7, Afzal A8.

Investigation of traditional medicinal floral knowledge of Sarban Hills, Abbottabad, KP, Pakistan

J Ethnopharmacol. 2016 Feb 17;179:208-33. doi: 10.1016/j.jep.2015.12.050. Epub 2015 Dec 29.

III

113

Inayat F1, Virk HU2, Ullah W3, Hussain Q4.

Is haloperidol the wonder drug for cannabinoid hyperemesis syndrome?

BMJ Case Rep. 2017 Jan 4;2017. pii: bcr2016218239. doi: 10.1136/bcr-2016-218239

III

114

Isaac S1, Saini B1, Chaar BB1

The Role of Medicinal Cannabis in Clinical Therapy: Pharmacists' Perspectives

PLoS One. 2016 May 12;11(5):e0155113. doi: 10.1371/journal.pone.0155113. 2016 May 12 2016.

III

115

Ismail AM, Dubrey SW, Patel MC.

Recurrent headaches: a case of neurological Behçet's disease.

Br J Hosp Med (Lond). 2013 Oct;74(10):592-3.

III

116

Jefferson DA, Harding HE, Cawich SO, Jackson-Gibson A.

Postoperative analgesia in the Jamaican cannabis user.

J Psychoactive Drugs. 2013 Jul-Aug;45(3):227-32.

Ib

117

Jensen B1, Chen J, Furnish T, Wallace M

Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence.

Curr Pain Headache Rep. 2015 Oct;19(10):50. doi: 10.1007/s11916-015-0524-x.

IV

118

Juurlink DN1.

Medicinal cannabis: time to lighten up?

CMAJ. 2014 Sep 2;186(12):897-8. doi: 10.1503/cmaj.140309. Epub 2014 Jun 23

IV

119

Kahan B1

Cancer pain and current theory for pain control

Phys Med Rehabil Clin N Am. 2014 May;25(2):439-56. doi: 10.1016/j.pmr.2014.01.013.

IV

120

Kahan M1, Srivastava A2, Spithoff S3, Bromley L4.

Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations.

Can Fam Physician. 2014 Dec;60(12):1083-90

III

121

Kaur R1, Ambwani SR, Singh S.

Endocannabinoid System: A Multi-Facet Therapeutic Target.

Curr Clin Pharmacol. 2016;11(2):110-7.

III

122

Kern AM1, Akerman SC, Nordstrom BR

Opiate dependence in schizophrenia: case presentation and literature review

J Dual Diagn. 2014;10(1):52-7. doi: 10.1080/15504263.2013.867199

III

123

Kim PS1, Fishman MA2.

Cannabis for Pain and Headaches: Primer.

Curr Pain Headache Rep. 2017 Apr;21(4):19. doi: 10.1007/s11916-017-0619-7.

III

124

Kleinloog D, Roozen F, De Winter W, Freijer J, Van Gerven J.

Profiling the subjective effects of Δ⁹-tetrahydrocannabinol using visual analogue scales

Int J Methods Psychiatr Res. 2014 Jun;23(2):245-56. doi: 10.1002/mpr.1424. Epub 2014 Feb 5.

III

125

Kondrad E

Medical marijuana for chronic pain

N C Med J. 2013 May-Jun;74(3):210-1.

IV

126

Koppel BS1, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D.

Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Neurology. 2014 Apr 29;82(17):1556-63. doi: 10.1212/WNL.0000000000000363.

Ia

127

Kral AH1, Wenger L2, Novak SP2, Chu D3, Corsi KF4, Coffa D5, Shapiro B6, Bluthenthal RN7.

Is cannabis use associated with less opioid use among people who inject drugs?

Drug Alcohol Depend. 2015 Aug 1;153:236-41. doi: 10.1016/j.drugalcdep.2015.05.014. Epub 2015 May 22.

III

128

Kramer JL1

Medical marijuana for cancer.

CA Cancer J Clin. 2015 Mar;65(2):109-22. doi: 10.3322/caac.21260. Epub 2014 Dec 10.

IV

129

Krawitz M1.

Veterans Health Administration Policy on Cannabis as an Adjunct to Pain Treatment with Opiates

AMA J Ethics. 2015 Jun 1;17(6):558-61. doi: 10.1001/journalofethics.2015.17.6.pfor2-1506.

IV

130

Kumar R1, Prasoon P1, Gautam M1, Ray SB1

Comparative antinociceptive effect of arachidonylcyclopropylamide, a cannabinoid 1 receptor agonist & lignocaine, a local anaesthetic agent, following direct intrawound administration in rats

Indian J Med Res. 2016 Nov;144(5):730-740. doi: 10.4103/ijmr.IJMR_1402_15

III

131

Ladouceur R.

Prescribing marijuana for chronic pain.

Can Fam Physician. 2015 Aug;61(8):658.

IV

132

Lake S, Kerr T, Montaner J1.

Prescribing medical cannabis in Canada: Are we being too cautious?

Can J Public Health. 2015 Apr 30;106(5):e328-30. doi: 10.17269/cjph.106.4926.

IV

133

Laprevote V1, Gambier N2, Cridlig J3, Savenkoff B4, Scala-Bertola J2, Hingray C5, Schwan R6

Early withdrawal effects in a heavy cannabis smoker during hemodialysis.

Biol Psychiatry. 2015 Mar 1;77(5):e25-6. doi: 10.1016/j.biopsych.2014.07.032. Epub 2014 Aug 23.

III

134

Lau N1, Sales P1, Averill S1, Murphy F1, Sato SO1, Murphy S1.

A safer alternative: Cannabis substitution as harm reduction

Drug Alcohol Rev. 2015 Nov;34(6):654-9. doi: 10.1111/dar.12275. Epub 2015 Apr 28.

III

135

Le Boisselier R1,2, Alexandre J2,3, Lelong-Boulouard V2,4, Debruyne D1,2,5.

Focus on cannabinoids and synthetic cannabinoids

Clin Pharmacol Ther. 2017 Feb;101(2):220-229. doi: 10.1002/cpt.563. Epub 2016 Dec 20

III

136

Lee MC1, Ploner M, Wiech K, Bingel U, Wanigasekera V, Brooks J, Menon DK, Tracey I.

Amygdala activity contributes to the dissociative effect of cannabis on pain perception.

Pain. 2013 Jan;154(1):124-34. doi: 10.1016/j.pain.2012.09.017.

IIa

137

Leleu-Chavain N1, Biot C, Chavatte P, Millet R

From cannabis to selective CB2R agonists: molecules with numerous therapeutical virtues

Med Sci (Paris). 2013 May;29(5):523-8. doi: 10.1051/medsci/2013295016. Epub 2013 May 28.

IV

138

Leroux E1, Taifas I, Valade D, Donnet A, Chagnon M, Ducros A

Use of cannabis among 139 cluster headache sufferers.

Cephalalgia. 2013 Feb;33(3):208-13. doi: 10.1177/0333102412468669. Epub 2012 Nov 29.

III

139

Levinthal DJ1, Bielefeldt K.

Adult cyclical vomiting syndrome: a disorder of allostatic regulation?

Exp Brain Res. 2014 Aug;232(8):2541-7. doi: 10.1007/s00221-014-3939-4. Epub 2014 Apr 16.

IV

140

Lin XH, Wang YQ, Wang HC, Ren XQ, Li YY.

Role of endogenous cannabinoid system in the gut.

Sheng Li Xue Bao. 2013 Aug 25;65(4):451-60.

IV

141

Lind JN, Petersen EE, Lederer PA, Phillips-Bell GS, Perrine CG, Li R, Hudak M, Correia JA, Creanga AA, Sappenfield WM, Curran J, Blackmore C, Watkins SM, Anjohrin S; Centers for Disease Control and Prevention (CDC)

Infant and maternal characteristics in neonatal abstinence syndrome--selected hospitals in Florida, 2010-2011.

MMWR Morb Mortal Wkly Rep. 2015 Mar 6;64(8):213-6.

III

142

Lotan I, Treves TA, Roditi Y, Djaldetti R.

Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study.

Clin Neuropharmacol. 2014 Mar-Apr;37(2):41-4. doi: 10.1097/WNF.0000000000000016.

III

143

Lu Y1,2, Anderson HD1,2,3.

Cannabinoid signaling in health and disease

Can J Physiol Pharmacol. 2017 Apr;95(4):311-327. doi: 10.1139/cjpp-2016-0346. Epub 2017 Mar 6.

III

144

Lup1.

Pain patients may grow their own cannabis

MMW Fortschr Med. 2016 Apr 14;158(7):29. doi: 10.1007/s15006-016-8047-x.

III

145

Maccarrone M1,2, Maldonado R3, Casas M4,5,6, Henze T7, Centonze D8.

Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?

Expert Rev Clin Pharmacol. 2017 Apr;10(4):443-455. doi: 10.1080/17512433.2017.1292849. Epub 2017 Feb 28.

III

146

Maione S1, Costa B, Di Marzo V.

Endocannabinoids: a unique opportunity to develop multitarget analgesics.

Pain. 2013 Dec;154 Suppl 1:S87-93. doi: 10.1016/j.pain.2013.03.023. Epub 2013 Mar 15.

IV

147

Malik Z1, Baik D, Schey R

The role of cannabinoids in regulation of nausea and vomiting, and visceral pain.

Curr Gastroenterol Rep. 2015 Feb;17(2):429. doi: 10.1007/s11894-015-0429-1.

IV

148

Marino S1, Idris AI2

Emerging therapeutic targets in cancer induced bone disease: A focus on the peripheral type 2 cannabinoid receptor.

Pharmacol Res. 2017 May;119:391-403. doi: 10.1016/j.phrs.2017.02.023. Epub 2017 Mar 6.

III

149

Mather LE, Rauwendaal ER, Moxham-Hall VL, Wodak AD.

(Re)introducing medicinal cannabis.

Med J Aust. 2013 Dec 16;199(11):759-61.

IV

150

McAllister SD1, Soroceanu L, Desprez PY

The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids

J Neuroimmune Pharmacol. 2015 Jun;10(2):255-67. doi: 10.1007/s11481-015-9608-y. Epub 2015 Apr 28.

IV

151

McCabe BE, Feaster DJ, Mitrani VB

Health correlates of co-occurring substance use for women with HIV in cocaine use recovery.

Addict Behav. 2014 Mar;39(3):725-8. doi: 10.1016/j.addbeh.2013.11.026. Epub 2013 Dec 3.

III

152

McGeeney BE1.

Cannabinoids and hallucinogens for headache.

Headache. 2013 Mar;53(3):447-58. doi: 10.1111/head.12025. Epub 2012 Dec 20.

IV

153

McNamara S, Stokes S, Kilduff R, Shine A.

Pregabalin Abuse amongst Opioid Substitution Treatment Patients.

Ir Med J. 2015 Nov-Dec;108(10):309-10

III

154

Meng H1, Hanlon JG1,2, Katznelson R1,3,4, Ghanekar A5, McGilvray I5, Clarke H6,7,8.

The prescription of medical cannabis by a transitional pain service to wean a patient with complex pain from opioid use following liver transplantation: a case report.

Can J Anaesth. 2016 Mar;63(3):307-10. doi: 10.1007/s12630-015-0525-6. Epub 2015 Oct 27.

III

155

Merlin JS1, Bulls HW2, Vucovich LA3, Edelman EJ4, Starrels JL5

Pharmacologic and non-pharmacologic treatments for chronic pain in individuals with HIV: a systematic review

AIDS Care. 2016 Dec;28(12):1506-1515. Epub 2016 Jun 7

III

156

Miller G1.

Pot and pain

Science. 2016 Nov 4;354(6312):566-568

III

157

Mills B1, Yepes A, Nugent K

Synthetic Cannabinoids.

Am J Med Sci. 2015 Jul;350(1):59-62. doi: 10.1097/MAJ.0000000000000466.

IV

158

Mücke M1,2,3, Carter C4, Cuhls H4, Prüß M5, Radbruch L4,6, Häuser W7,

Cannabinoids in palliative care: Systematic review and meta-analysis of efficacy, tolerability and safety

Schmerz. 2016 Feb;30(1):25-36. doi: 10.1007/s00482-015-0085-2

Ia

159

Müller-Vahl K.

In reply.

Dtsch Arztebl Int. 2013 Mar;110(10):175. doi: 10.3238/arztebl.2013.0175. Epub 2013 Mar 8.

IV

160

Muschart X, Flament J.

A non-classical cannabinoid syndrome

Acta Clin Belg. 2015 Aug;70(4):299-300. doi: 10.1179/2295333714Y.0000000116. Epub 2015 Jan 8.

IV

161

Naftali T1, Mechulam R, Lev LB, Konikoff FM.

Cannabis for inflammatory bowel disease

Dig Dis. 2014;32(4):468-74. doi: 10.1159/000358155. Epub 2014 Jun 23.

III

162

Nazarzadeh M, Bidel Z, Carson KV

The association between tramadol hydrochloride misuse and other substances use in an adolescent population: Phase I of a prospective survey.

Addict Behav. 2014 Jan;39(1):333-7. doi: 10.1016/j.addbeh.2013.09.013. Epub 2013 Sep 14.

IIa

163

Ngatchou W1, Lemogoum D2, Essola B2, Ramadan A3, Ngassa M4, Guimfacq V5, Mols P3, Towo PY3.

Cannabis body packing: a case report

Pan Afr Med J. 2016 Aug 30;24:327. doi: 10.11604/pamj.2016.24.327.9450. eCollection 2016

III

164

Nikan M1, Nabavi SM2, Manayi A3

Ligands for cannabinoid receptors, promising anticancer agents.

Life Sci. 2016 Feb 1;146:124-30. doi: 10.1016/j.lfs.2015.12.053. Epub 2016 Jan 5.

IV

165

Norton C1, Czuber-Dochan W1, Artom M1, Sweeney L1, Hart A2

Systematic review: interventions for abdominal pain management in inflammatory bowel disease

Aliment Pharmacol Ther. 2017 Jul;46(2):115-125. doi: 10.1111/apt.14108. Epub 2017 May 4.

III

166

Notcutt WG1.

A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine.

Prim Health Care Res Dev. 2013 Apr;14(2):192-9. doi: 10.1017/S1463423612000333. Epub 2012 Jul 12.

III

167

Novak SP1, Peiper NC2, Zarkin GA3.

Nonmedical prescription pain reliever and alcohol consumption among cannabis users

Drug Alcohol Depend. 2016 Feb 1;159:101-8. doi: 10.1016/j.drugalcdep.2015.11.039. Epub 2015 Dec 17.

III

168

Nugent SM1, Morasco BJ1, O'Neil ME1, Freeman M1, Low A1, Kondo K1, Elven C1, Zakher B1, Motu'apuaka M1, Paynter R1, Kansagara D1

The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms: A Systematic Review.

Ann Intern Med. 2017 Sep 5;167(5):319-331. doi: 10.7326/M17-0155. Epub 2017 Aug 15

III

169

Obafemi AI1, Kleinschmidt K2, Goto C2, Fout D3

Cluster of Acute Toxicity from Ingestion of Synthetic Cannabinoid-Laced Brownies

J Med Toxicol. 2015 Dec;11(4):426-9. doi: 10.1007/s13181-015-0482-z.

III

170

Ormachea O1, Bernasconi E2, Pons M2, Fusi-Schmidhauser T2

Wiederkehrende abdominelle Schmerzen, Übelkeit und heisses Baden – eine neue Trias?

Praxis (Bern 1994). 2017;106(11):595-597. doi: 10.1024/1661-8157/a002694

IV

171

Ossato A1, Canazza I1, Trapella C2, Vincenzi F3, De Luca MA4, Rimondo C5, Varani K3, Borea PA3, Serpelloni G6, Marti M7.

Effect of JWH-250, JWH-073 and their interaction on "tetrad", sensorimotor, neurological and neurochemical responses in mice.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jun 3;67:31-50. doi: 10.1016/j.pnpbp.2016.01.007. Epub 2016 Jan 15.

IIa

172

Ostadhadi S1, Rahmatollahi M, Dehpour AR, Rahimian R

Therapeutic potential of cannabinoids in counteracting chemotherapy-induced adverse effects: an exploratory review.

Phytother Res. 2015 Mar;29(3):332-8. doi: 10.1002/ptr.5265. Epub 2014 Dec 12.

IV

173

Pacher P1.

Towards the use of non-psychoactive cannabinoids for prostate cancer

Br J Pharmacol. 2013 Jan;168(1):76-8. doi: 10.1111/j.1476-5381.2012.02121.x.

IV

174

Page J1, Ware M2.

Perspective: Close the knowledge gap.

Nature. 2015 Sep 24;525(7570):S9. doi: 10.1038/525S9a.

IV

175

Pain S.

A potted history.

Nature. 2015 Sep 24;525(7570):S10-1. doi: 10.1038/525S10a.

IV

176

Palmieri B1,2, Laurino C1,2, Vadalà M1,2.

Short-Term Efficacy of CBD-Enriched Hemp Oil in Girls with Dysautonomic Syndrome after Human Papillomavirus Vaccination

Isr Med Assoc J. 2017 Feb;19(2):79-84.

III

177

Parmar JR1, Forrest BD2, Freeman RA2.

Medical marijuana patient counseling points for health care professionals based on trends in the medical uses, efficacy, and adverse effects of cannabis-based pharmaceutical drugs

Res Social Adm Pharm. 2016 Jul-Aug;12(4):638-54. doi: 10.1016/j.sapharm.2015.09.002. Epub 2015 Sep 16.

Ia

178

Patel S1.

Cannabis for Pain and Posttraumatic Stress Disorder: More Consensus Than Controversy or Vice Versa?

Ann Intern Med. 2017 Sep 5;167(5):355-356. doi: 10.7326/M17-1713. Epub 2017 Aug 15.

III

179

Pearce DD1, Mitsouras K, Irizarry KJ.

Discriminating the effects of Cannabis sativa and Cannabis indica: a web survey of medical cannabis users

J Altern Complement Med. 2014 Oct;20(10):787-91. doi: 10.1089/acm.2013.0190. Epub 2014 Sep 5.

III

180

Pedro E, Rodríguez FM.

Use and medicalization of marihuana in cancer patients.

Bol Asoc Med P R. 2014;106(3):55-9.

IV

181

Pélissier F1, Claudet I2, Gandia-Mailly P3, Benyamina A4, Franchitto N5.

Cannabis Hyperemesis Syndrome in the Emergency Department: How Can a Specialized Addiction Team Be Useful? A Pilot Study.

J Emerg Med. 2016 Nov;51(5):544-551. doi: 10.1016/j.jemermed.2016.06.009. Epub 2016 Jul 30

III

182

Pergam SA1,2,3,4, Woodfield MC1, Lee CM5,6, Cheng GS2,3, Baker KK2, Marquis SR1, Fann JR2,5

Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use

Cancer. 2017 Nov 15;123(22):4488-4497. doi: 10.1002/cncr.30879. Epub 2017 Sep 25.

III

183

Perron BE1, Bohnert K2,3, Perone AK1, Bonn-Miller MO4,5,6,7, Ilgen M2,3.

Use of prescription pain medications among medical cannabis patients: comparisons of pain levels, functioning, and patterns of alcohol and other drug use.

J Stud Alcohol Drugs. 2015 May;76(3):406-13.

III

184

Petzke F1, Enax-Krumova EK2, Häuser W3,4.

Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies

Schmerz. 2016 Feb;30(1):62-88. doi: 10.1007/s00482-015-0089-y.

Ia

185

Pledger M1, Martin G, Cumming J.

New Zealand Health Survey 2012/13: characteristics of medicinal cannabis users.

N Z Med J. 2016 Apr 22;129(1433):25-36

III

186

Pozzilli C

Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.

Expert Rev Neurother. 2013 Dec;13(12 Suppl):49-54. doi: 10.1586/14737175.2013.865877.

IV

187

Rabner J1, Gottlieb S1, Lazdowsky L1, LeBel A1.

Psychosis following traumatic brain injury and cannabis use in late adolescence.

Am J Addict. 2016 Mar;25(2):91-3. doi: 10.1111/ajad.12338. Epub 2016 Feb 5.

III

188

Raffray L1, Renou F2, Bourdier-de-Beauregard M3, Lartigau-Roussin C3, Mohamed S4

Vomiting and abdominal pain in a 29-year-old man

Rev Med Interne. 2017 Jan;38(1):65-68. doi: 10.1016/j.revmed.2016.07.003. Epub 2016 Oct 13.

III

189

Rauenzahn S1, Sima A1, Cassel B1, Noreika D1, Gomez TH1, Ryan L1, Wolf CE1, Legakis L1, Del Fabbro E2.

Urine drug screen findings among ambulatory oncology patients in a supportive care clinic.

Support Care Cancer. 2017 Jun;25(6):1859-1864. doi: 10.1007/s00520-017-3575-1. Epub 2017 Jan 25.

III

190

Ravikoff Allegretti J, Courtwright A, Lucci M, Korzenik JR, Levine J.

Marijuana use patterns among patients with inflammatory bowel disease

Inflamm Bowel Dis. 2013 Dec;19(13):2809-14. doi: 10.1097/01.MIB.0000435851.94391.37.

IIb

191

Reisfield GM1, Shults T, Demery J, Dupont R.

A protocol to evaluate drug-related workplace impairment

J Pain Palliat Care Pharmacother. 2013 Mar;27(1):43-8. doi: 10.3109/15360288.2012.753975.

III

192

Rivera-Olmos VM1, Parra-Bernal MC

Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences

Rev Med Inst Mex Seguro Soc. 2016 Sep-Oct;54(5):626-34.

III

193

Robertson JR1, Robertson AR

Responding to illicit drug use in family practice

Curr Opin Psychiatry. 2015 Jul;28(4):286-91. doi: 10.1097/YCO.0000000000000174.

IV

194

Robson PJ

Therapeutic potential of cannabinoid medicines.

Drug Test Anal. 2014 Jan-Feb;6(1-2):24-30. doi: 10.1002/dta.1529. Epub 2013 Sep 4.

IV

195

Rogers MA1, Lemmen K1, Kramer R1, Mann J1, Chopra V1

Internet-Delivered Health Interventions That Work: Systematic Review of Meta-Analyses and Evaluation of Website Availability.

J Med Internet Res. 2017 Mar 24;19(3):e90. doi: 10.2196/jmir.7111

- -

196

Romero K1, Pavisian B1, Staines WR2, Feinstein A1.

Multiple sclerosis, cannabis, and cognition: A structural MRI study.

Neuroimage Clin. 2015 Apr 9;8:140-7. doi: 10.1016/j.nicl.2015.04.006. eCollection 2015.

IV

197

Romero-Sandoval EA1, Asbill S1, Paige CA1, Byrd-Glover K1.

Peripherally Restricted Cannabinoids for the Treatment of Pain.

Pharmacotherapy. 2015 Oct;35(10):917-25. doi: 10.1002/phar.1642.

IV

198

Rowe J1, Caprio AJ.

Chronic pain: challenges and opportunities for relieving suffering

N C Med J. 2013 May-Jun;74(3):201-4.

IV

199

Rowley E1, Benson D2, Tiffee A2, Hockensmith A3, Zeng H4, Jones GN5, Musso MW6

Clinical and financial implications of emergency department visits for synthetic marijuana

Am J Emerg Med. 2017 Oct;35(10):1506-1509. doi: 10.1016/j.ajem.2017.04.044. Epub 2017 Apr 23

III

200

Roy-Byrne P1, Maynard C2, Bumgardner K1, Krupski A1, Dunn C1, West II1, Donovan D1, Atkins DC1, Ries R1

Are medical marijuana users different from recreational users? The view from primary care

Am J Addict. 2015 Oct;24(7):599-606. doi: 10.1111/ajad.12270. Epub 2015 Sep 4

III

201

Ruchlemer R1, Amit-Kohn M, Raveh D, Hanuš L

Inhaled medicinal cannabis and the immunocompromised patient

Support Care Cancer. 2015 Mar;23(3):819-22. doi: 10.1007/s00520-014-2429-3. Epub 2014 Sep 13.

III

202

Russo EB1, Marcu J2.

Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads

Adv Pharmacol. 2017;80:67-134. doi: 10.1016/bs.apha.2017.03.004. Epub 2017 Jun 5.

III

203

Ryan-Ibarra S1, Induni M, Ewing D

Prevalence of medical marijuana use in California, 2012

Drug Alcohol Rev. 2015 Mar;34(2):141-6. doi: 10.1111/dar.12207. Epub 2014 Sep 26.

III

204

Sagie S, Eliasi Y, Livneh I, Bart Y, Monovich E

Short-and long-term effects of cannabinoids on memory, cognition and mental illness

Harefuah. 2013 Dec;152(12):737-41, 751.

IV

205

Savage SR1, Romero-Sandoval A2, Schatman M3, Wallace M4, Fanciullo G5, McCarberg B4, Ware M6.

Cannabis in Pain Treatment: Clinical and Research Considerations.

J Pain. 2016 Jun;17(6):654-68. doi: 10.1016/j.jpain.2016.02.007. Epub 2016 Mar 4.

III

206

Sayın MR, Akpınar İ, Çetiner MA, Karabağ T.

Diffuse coronary ectasia and acute coronary syndrome in a young man. Who is guilty? Cannabis, smoking or dyslipidemia?

nadolu Kardiyol Derg. 2013 Sep;13(6):616-8. doi: 10.5152/akd.2013.212. Epub 2013 Sep 10.

III

207

Scheidweiler KB1, Himes SK, Chen X, Liu HF, Huestis MA

11-Nor-9-carboxy-∆9-tetrahydrocannabinol quantification in human oral fluid by liquid chromatography-tandem mass spectrometry.

Anal Bioanal Chem. 2013 Jul;405(18):6019-27. doi: 10.1007/s00216-013-7027-6. Epub 2013 May 17.

III

208

Schrot RJ1,2, Hubbard JR3,4.

Cannabinoids: Medical implications

Ann Med. 2016;48(3):128-41. doi: 10.3109/07853890.2016.1145794. Epub 2016 Feb 25.

III

209

Sharkey KA1, Wiley JW2.

The Role of the Endocannabinoid System in the Brain-Gut Axis.

Gastroenterology. 2016 Aug;151(2):252-66. doi: 10.1053/j.gastro.2016.04.015. Epub 2016 Apr 29.

III

210

Sherman BJ1, McRae-Clark AL1, Baker NL2, Sonne SC1, Killeen TK1, Cloud K3, Gray KM1.

Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the achieving cannabis cessation-evaluating N-acetylcysteine treatment (ACCENT) study.

Am J Addict. 2017 Mar;26(2):136-144. doi: 10.1111/ajad.12503. Epub 2017 Feb 2

Ib

211

Smith SC, Wagner MS

Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

Neuro Endocrinol Lett. 2014;35(3):198-201.

IV

212

Sorensen CJ1, DeSanto K2, Borgelt L3, Phillips KT4, Monte AA5,6,7.

Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review.

J Med Toxicol. 2017 Mar;13(1):71-87. doi: 10.1007/s13181-016-0595-z. Epub 2016 Dec 20

III

213

Soyka M1,2,3, Preuss U4, Hoch E5.

Cannabis-induced disorders

Nervenarzt. 2017 Mar;88(3):311-325. doi: 10.1007/s00115-017-0281-7.

III

214

Stacey BR, Moller JL.

Marijuana for pain relief: don't jump to conclusions.

J Pain. 2013 Oct;14(10):1250-1. doi: 10.1016/j.jpain.2013.07.002.

IV

215

Starowicz K1, Di Marzo V.

Non-psychotropic analgesic drugs from the endocannabinoid system: "magic bullet" or "multiple-target" strategies?

Eur J Pharmacol. 2013 Sep 15;716(1-3):41-53. doi: 10.1016/j.ejphar.2013.01.075. Epub 2013 Mar 13.

IV

216

Stavros K1, Simpson DM

Understanding the etiology and management of HIV-associated peripheral neuropathy

Curr HIV/AIDS Rep. 2014 Sep;11(3):195-201. doi: 10.1007/s11904-014-0211-2.

III

217

Ste-Marie PA1, Shir Y, Rampakakis E, Sampalis JS, Karellis A, Cohen M, Starr M, Ware MA, Fitzcharles MA.

Survey of herbal cannabis (marijuana) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis.

Pain. 2016 Dec;157(12):2792-2797

III

218

Stern P, Roberts L.

The future of pain research

Science. 2016 Nov 4;354(6312):564-565.

III

219

Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN.

Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease.

Inflamm Bowel Dis. 2014 Mar;20(3):472-80. doi: 10.1097/01.MIB.0000440982.79036.d6.

IIa

220

Strouse TB1.

Pot in palliative care: what we need to know

J Palliat Med. 2015 Jan;18(1):7-10. doi: 10.1089/jpm.2015.0003.

IV

221

Svrakic DM.

Mary Jane still dulls the pain

Mo Med. 2013 Mar-Apr;110(2):121.

IV

222

Temple LM.

Medical marijuana and pain management

Dis Mon. 2016 Sep;62(9):346-52. doi: 10.1016/j.disamonth.2016.05.014. Epub 2016 Jun 27.

III

223

Thankavel PP1, Mir A1, Ramaciotti C1.

Elevated troponin levels in previously healthy children: value of diagnostic modalities and the importance of a drug screen

Cardiol Young. 2014 Apr;24(2):283-9. doi: 10.1017/S1047951113000231. Epub 2013 Mar 5.

III

224

Thorson D.

Questions about medical cannabis linger.

Minn Med. 2016 Jan-Feb;99(1):28.

III

225

Tsui JI1, Cheng DM, Coleman SM, Blokhina E, Bridden C, Krupitsky E, Samet JH

Pain is associated with heroin use over time in HIV-infected Russian drinkers

Addiction. 2013 Oct;108(10):1779-87. doi: 10.1111/add.12274. Epub 2013 Jul 24.

III

226

Turgeman I1, Bar-Sela G1,2.

Cannabis Use in Palliative Oncology: A Review of the Evidence for Popular Indications

Isr Med Assoc J. 2017 Feb;19(2):85-88.

III

227

Underner M1, Perriot J2, Peiffer G3

Pneumomediastinum and cocaine use

Presse Med. 2017 Mar;46(3):249-262. doi: 10.1016/j.lpm.2017.01.002. Epub 2017 Feb 8

III

228

Vaessen T1, Hernaus D2, Myin-Germeys I2, van Amelsvoort T2.

The dopaminergic response to acute stress in health and psychopathology: A systematic review.

Neurosci Biobehav Rev. 2015 Sep;56:241-51. doi: 10.1016/j.neubiorev.2015.07.008. Epub 2015 Jul 19.

III

229

Vic P1, Ramé E2, Robert-Dehault A2, Henry S2, Le Moigno L2, Hébert J2

Adolescents in the Pediatric Emergency Department: Detection of risk behavior and depression

Arch Pediatr. 2015 Jun;22(6):580-94. doi: 10.1016/j.arcped.2015.03.004. Epub 2015 Apr 18.

III

230

Vigolo A1, Ossato A1, Trapella C2, Vincenzi F3, Rimondo C4, Seri C4, Varani K3, Serpelloni G4, Marti M5.

Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice

Neuropharmacology. 2015 Aug;95:68-82. doi: 10.1016/j.neuropharm.2015.02.008. Epub 2015 Mar 11.

IIa

231

Vingilis E1, Mann RE, Erickson P, Toplak M, Kolla NJ, Seeley J, Jain U.

Attention deficit hyperactivity disorder, other mental health problems, substance use, and driving: examination of a population-based, representative canadian sample.

Traffic Inj Prev. 2014;15 Suppl 1:S1-9. doi: 10.1080/15389588.2014.926341.

III

232

Volz MS1, Siegmund B1, Häuser W2,3.

Efficacy, tolerability, and safety of cannabinoids in gastroenterology: A systematic review

Schmerz. 2016 Feb;30(1):37-46. doi: 10.1007/s00482-015-0087-0

Ia

233

Waissengrin B1, Urban D2, Leshem Y2, Garty M1, Wolf I3

Patterns of use of medical cannabis among Israeli cancer patients: a single institution experience

)J Pain Symptom Manage. 2015 Feb;49(2):223-30. doi: 10.1016/j.jpainsymman.2014.05.018. Epub 2014 Jun 14.

III

234

Walitt B1, Klose P, Fitzcharles MA, Phillips T, Häuser W.

Cannabinoids for fibromyalgia

Cochrane Database Syst Rev. 2016 Jul 18;7:CD011694. doi: 10.1002/14651858.CD011694.pub2.

Ia

235

Wallace MS1, Marcotte TD2, Umlauf A2, Gouaux B2, Atkinson JH3

Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy

J Pain. 2015 Jul;16(7):616-27. doi: 10.1016/j.jpain.2015.03.008. Epub 2015 Apr 3

Ib

236

Walsh Z, Callaway R, Belle-Isle L, Capler R, Kay R, Lucas P, Holtzman S

Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use

Int J Drug Policy. 2013 Nov;24(6):511-6. doi: 10.1016/j.drugpo.2013.08.010. Epub 2013 Sep 9.

III

237

Ware MA1, Wang T2, Shapiro S3, Collet JP4; COMPASS study team.

Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS).

J Pain. 2015 Dec;16(12):1233-1242. doi: 10.1016/j.jpain.2015.07.014. Epub 2015 Sep 16.

IIa

238

Ware MA1,2, Ziemianski D2

Medical education on cannabis and cannabinoids: Perspectives, challenges, and opportunities

Clin Pharmacol Ther. 2015 Jun;97(6):548-50. doi: 10.1002/cpt.103.

IV

239

Warner B, Cairns S, Stone A.

A rare case of cannabis hyperemesis syndrome relieved by hot water bathing.

Clin Med (Lond). 2014 Feb;14(1):86-7. doi: 10.7861/clinmedicine.14-1-86.

III

240

Webb CW1, Webb SM1

Therapeutic benefits of cannabis: a patient survey.

Hawaii J Med Public Health. 2014 Apr;73(4):109-11.

III

241

Whiting PF1, Wolff RF2, Deshpande S2, Di Nisio M3, Duffy S2, Hernandez AV4, Keurentjes JC5, Lang S2, Misso K2, Ryder S2, Schmidlkofer S6, Westwood M2, Kleijnen J7.

Cannabinoids for Medical Use: A Systematic Review and Meta-analysis

JAMA. 2015 Jun 23-30;313(24):2456-73. doi: 10.1001/jama.2015.635

Ia

242

Wilkinson ST1, Yarnell S1, Radhakrishnan R1,2,3, Ball SA1,2,4, D'Souza DC1,2,3.

Marijuana Legalization: Impact on Physicians and Public Health.

Annu Rev Med. 2016;67:453-66. doi: 10.1146/annurev-med-050214-013454. Epub 2015 Oct 19.

IV

243

Wilsey B, Marcotte T, Deutsch R.

Response to Stacey and Moller's letter to the editor.

J Pain. 2013 Oct;14(10):1252-3. doi: 10.1016/j.jpain.2013.07.003.

IV

244

Wilsey B1, Atkinson JH, Marcotte TD, Grant I

The Medicinal Cannabis Treatment Agreement: Providing Information to Chronic Pain Patients Through a Written Document.

Clin J Pain. 2015 Dec;31(12):1087-96. doi: 10.1097/AJP.0000000000000145.

III

245

Wilsey B1, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H.

Low-dose vaporized cannabis significantly improves neuropathic pain.

J Pain. 2013 Feb;14(2):136-48. doi: 10.1016/j.jpain.2012.10.009. Epub 2012 Dec 11.

IIa

246

Wilsey B1, Marcotte TD2, Deutsch R2, Zhao H3, Prasad H3, Phan A3

Neuropathic Pain From Spinal Cord Injury and Disease

J Pain. 2016 Sep;17(9):982-1000. doi: 10.1016/j.jpain.2016.05.010. Epub 2016 Jun 7.

Ia

247

Winter K, Ritter R, Viera AJ.

Painful ear nodules.

J Fam Pract. 2013 Sep;62(9):503-5.

IV

248

Wolff V1, Armspach JP, Lauer V, Rouyer O, Ducros A, Marescaux C, Gény B.

Ischaemic strokes with reversible vasoconstriction and without thunderclap headache: a variant of the reversible cerebral vasoconstriction syndrome?

Cerebrovasc Dis. 2015;39(1):31-8. doi: 10.1159/000369776. Epub 2014 Dec 24.

IIa

249

Wolff V1,2, Ducros A3.

Reversible Cerebral Vasoconstriction Syndrome Without Typical Thunderclap Headache

Headache. 2016 Apr;56(4):674-87. doi: 10.1111/head.12794. Epub 2016 Mar 26.

- -

250

Wong SS1, Wilens TE2

Medical Cannabinoids in Children and Adolescents: A Systematic Review

American Academy of Pediatrics

Ia

251

Woodhams SG1, Sagar DR, Burston JJ, Chapman V.

The role of the endocannabinoid system in pain

Handb Exp Pharmacol. 2015;227:119-43. doi: 10.1007/978-3-662-46450-2_7.

IV

252

Woods JA, Wright NJ, Gee J, Scobey MW

Cannabinoid Hyperemesis Syndrome: An Emerging Drug-Induced Disease.

Am J Ther. 2016 Mar-Apr;23(2):e601-5. doi: 10.1097/MJT.0000000000000034.

III

253

Wörz R.

Limited range of indications for cannabis

Dtsch Arztebl Int. 2013 Mar;110(10):174. doi: 10.3238/arztebl.2013.0174b. Epub 2013 Mar 8.

IV

254

Yadav V, Bever C Jr, Bowen J, Bowling A, Weinstock-Guttman B, Cameron M, Bourdette D, Gronseth GS, Narayanaswami P.

Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology.

Neurology. 2014 Mar 25;82(12):1083-92. doi: 10.1212/WNL.0000000000000250.

Ia

255

Yadav V1, Narayanaswami P2.

Complementary and alternative medical therapies in multiple sclerosis--the American Academy of Neurology guidelines: a commentary.

Clin Ther. 2014 Dec 1;36(12):1972-8. doi: 10.1016/j.clinthera.2014.10.011. Epub 2014 Nov 15.

IV

256

Yuan HB, Ho ST.

Cannabis in pain medicine still has a long way to go

Acta Anaesthesiol Taiwan. 2013 Dec;51(4):139-40. doi: 10.1016/j.aat.2013.12.006. Epub 2014 Jan 20.

IV

257

Zaller N1, Topletz A, Frater S, Yates G, Lally M

Profiles of medicinal cannabis patients attending compassion centers in rhode island

J Psychoactive Drugs. 2015 Jan-Mar;47(1):18-23. doi: 10.1080/02791072.2014.999901.

III

258

Zdrojewicz Z, Pypno D, Cabała K, Bugaj B, Waracki M.

Potential applications of marijuana and cannabinoids in medicine

Pol Merkur Lekarski. 2014 Oct;37(220):248-52.

IV

259

Ziemianski D1, Capler R2, Tekanoff R3, Lacasse A4, Luconi F5, Ware MA6.

Cannabis in medicine: a national educational needs assessment among Canadian physicians

BMC Med Educ. 2015 Mar 19;15:52. doi: 10.1186/s12909-015-0335-0.

III